Clinical Trials
Investigator | Collaborator | Research Title | Years |
MEJ. BERSEKUTU (PA) PROF. MADYA DR. MOHD YAZID BIN BAJURI (Jabatan Ortopedik & Traumatologi) | Dana Padanan Kolaborasi | Efficacy Of WF10 in Treatment of Diabetic Neuropathic Wound: A Prospective Controlled Study | 2/2021-7/2021 |
PROF. DR. NORLAILA BINTI MUSTAFA (Jabatan Perubatan) | Abbott Manufacturing Singapore Pte Ltd | A Randomized Controlled Trial To Determine The Effects Of A Diabetes-Specific Formula On Long-Term Glycemic Control And Short-Term Glycemic Variability In Individuals With Type 2 Diabetes | 2021-2023 |
DR. WONG ZHIQIN (Jabatan Perubatan) | Janssen Pharmaceutical Companies of Johnson & Johnson | A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | 2021-2025 |
PROF. DATO’ DR. FUAD BIN ISMAIL (Jabatan Radioterapi & Onkologi) | Arcus Biosciences, Inc | A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2021-2025 |
DR. NUR AFDZILLAH BINTI ABDUL RAHMAN (Jabatan Surgeri), | Tanpa biaya | Randomized controlled trial comparing the efficacy of Lactulose versus Polyethylene Glycol as Bowel preparation Agent for Colonoscopy | 2021-2022 |
PROF. DR. RAJA AFFENDI BIN RAJA ALI (Jabatan Perubatan) | Geran Pembiayaan Sepadan | Tocotrienol as a Treatment for Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial | 2020-2022 |
PROF. DR. ABDUL HALIM BIN ABDUL GAFOR (Jabatan Perubatan) | Visterra, Inc. | A Multicenter, Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy | 2020-2022 |
MEJ. BERSEKUTU (PA) PROF. MADYA DR MOHD YAZID BIN BAJURI (Jabatan Ortopedik & Traumatologi)
| OXO Translational Science GmbH
| Safety And Efficacy Of WF10 For Diabetes-Related Vascular Diseases: A Prospective Controlled Study
| 2020-2022 |
PROF. MADYA DR. ADAWIYAH BINTI JAMIL (Jabatan Perubatan) | AbbVie Inc. | M19-850: A Phase 3b, Open-Label Treatment Extension Study Of Upadacitinib For The Treatment Of Adult Subjects With Moderate To Severe Atopic Dermatitis Who Completed Treatment In Study M16-046 | 2020-2023 |
PROF. DR. ABDUL HALIM BIN ABDUL GAFOR (Jabatan Perubatan) | The George Institute for Global Health
| Treatment of cardiovascular disease with low dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) | 2020-2025 |
PROF. DR. MAE-LYNN CATHERINE BASTION (Jabatan Oftalmologi) | Alcon Laboratories (Malaysia) Sdn. Bhd. | Comparison of 23G UltravitTM and 27G UltravitTM Vitrectomy for Patient Comfort and Ocular Surface Disease | 2020-2021 |
PROF. MADYA DR. RABANI BINTI REMLI (Jabatan Perubatan)
| Merck Healthcare | Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety | 2020-2025 |
PROF. MADYA DR. NOR RAFEAH BINTI TUMIAN (Jabatan Perubatan)
| Hoffmann-La Roche Ltd | A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Crovalimab Versus 14.Eculizumab In Adult And Adolescent Pat15.ients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Comple | 2020-2025 |
PROF. DR. BARIAH BT. MOHD. ALI (Pusat Kajian Kesihatan Komuniti (ReaCH)) | Geran Universiti Penyelidikan (GUP) | Randomised clinical trial of controlling myopia progression in Malay primary school children using newly designed spectacles lenses | 2020-2025 |
DR. MUHAMMAD ISHAMUDDIN BIN ISMAIL (Jabatan Surgeri) | Y.S.P Industries (M) Sdn. Bhd. | Effect of Ionic Silver and Chlorhexidine (SiO2- Ag+ Chlorex) Spray on Pain and Reepithelialisation Rate in Donor Site Wounds for Patients Undergoing Split Skin Grafting (SSG) – A Study Protocol | 2020-2022 |
PROF. MADYA DR. HALIZA BINTI KATAS (Fakulti Farmasi) | Skim Geran Penyelidikan Pembangunan Prototaip (PRGS) | Upscaling, Safety and Efficacy of Multifaceted Dressing Embedded with DsiRNA-loaded Gold Nanoparticles for Diabetic Wound Treatment | 2020-2022 |
PROFESOR S FADILAH ABDUL WAHID (Pusat Terapi Sel) | Gaia Therapeutics Sdn Bhd | A Phase II/III Randomised, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed/ Refractory B-Acute Lymphoblastic Leukaemia | 2019-2024 |
PROFESOR DR RAJA AFFENDI RAJA ALI (Jabatan Perubatan) | Abbvie Inc. | M14-675: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis | 2019-2024 |
PROFESOR MADYA DR NORSHAMSIAH MD DIN (Jabatan Oftalmologi) | Singapore Eye Research Institute | The Asia Primary Tube Versus Trab (TVT) Study | 2019-2024 |
PROFESOR DR RAJA AFFENDI RAJA ALI (Jabatan Perubatan) | Abbvie Inc. | M16-067: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study To Evaluate The Efficacy And Safety Of Risankizumab In Subjects With Moderately To Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy | 2019-2024 |
PROF. DR. S. FADILAH S. ABDUL WAHID (Pusat Terapi Sel) | Hasumi International Research Foundation | A Phase II Randomised Study to Evaluate Safety and Efficacy of Intravenous Injection of Autologous Dendritic Cells & T Cell in Combination with Standard First Line Chemotherapy for the Treatment of Newly Diagnosed B Cell Non-Hodgkin Lymphoma | 2019-2024 |
PROFESOR DR RAJA AFFENDI RAJA ALI (Jabatan Perubatan) | Abbvie Inc. | M16-066:A Multicenter,Randomized,Double-Blind,Placebo-Controlled 52-Week Maintenance And An Open Label Extension Study Of The Efficacy And Safety Of Risankizumab In Subjects With Ulcerative Colitis Who Responded To Induction Treatment In M16-067 0R 065 | 2019-2024 |
PROFESOR DATO’ DR FUAD ISAMIL (Jabatan Radioterapi & Onkologi) | Regeneron Pharmaceuticals, Inc. | A Two-Part Randomized, Phase 3 Study Of Combinations Of Cemiplimab (ANTI-PD-1 ANTIBODY) And Platinum-Based Doublet Chemotherapy In First-Line Treatment Of Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer | 2019-2023 |
